Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease

Abstract

Patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) display a dismal prognosis and their therapy represents an unmet medical need, as the best treatment strategy is yet to be determined. Exciting data on novel targeted agents are now emerging from recently concluded and ongoing clinical trials in patients with relapsed and refractory CTCL. Three FDA approved compounds are used as single agents including the oral retinoid bexarotene and histone deacetylase inhibitors romidepsin and vorinostat. Brentuximab vedotin, an anti-CD30 drug-conjugated monoclonal antibody, has received from European Commission the orphan designation but has not been approved by EMA yet. Several other molecules have demonstrated their activity in the same context and combination strategies are being explored. Participation in a well designed clinical trial is encouraged, as the introduction of novel agents will continue to expand the therapeutics options available in the management of CTCL.

Keywords: ARGX-110; Bortezomib; Brentuximab vedotin; Copanlisib; Forodesine; Gemcitabine; HDAC inhibitors; IPH4102; Ipilimumab; Mogamulizumab; NM-IL-12; Nivolumab; Panobinostat; Pegylated liposomal doxorubicin; Pentostatin; Pralatrexate; Romidepsin; Toll-like receptor agonists; Zanolimumab; cutaneous T-cell lymphoma.